Our long-term goal is to produce and commercialize a novel class of oligotherapy products for the treatment of cancer, infectious and genetic diseases.
In the short-term we aim to establish a custom service for compound development and initiate ZATA’s IP licensing for specific drugs. Importantly in this stage, we will perform preclinical studies to obtain a proof of concept in several disease models, licensing of which will allow us to generate funding to support internal technology development.
ZATA Pharmaceuticals, Inc. is a small start-up that was founded in 2008 and is structured as a privately held C-Corporation.
ZATA is based in Worcester, MA at the Massachusetts Biomedical Initiatives (MBI) facilities.
ZATA is in the process of developing cutting-edge nucleic acid chemistry platform technology which will increase the clinical efficacy of novel oligotherapeutics for therapy approaches such as siRNA, micro-RNA and antisense therapies.
More details about our technology development can be found by linking to our research page